ERBB2 and breast cancer: Furthermore, there is an ongoing clinical trial investigating the effect of 223Ra-dichloride (55 kBq/kg) in HER2 negative, hormone-positive BC patients with bone metastases treated with exemestane and everolimus (NCT02258451).